A Single Arm, Open-label, Multicenter Study Evaluating the Long-term Safety and Tolerability of 0.5 mg Fingolimod (FTY720) Administered Orally Once Daily in Patients With Relapsing Forms of Multiple Sclerosis

Trial Profile

A Single Arm, Open-label, Multicenter Study Evaluating the Long-term Safety and Tolerability of 0.5 mg Fingolimod (FTY720) Administered Orally Once Daily in Patients With Relapsing Forms of Multiple Sclerosis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Registrational
  • Acronyms LONGTERMS
  • Sponsors Novartis
  • Most Recent Events

    • 06 Apr 2017 The trial has been completed in Ireland according to Eudra.
    • 08 Jun 2016 Last checked against United Kingdom Clinical Research Network record.
    • 21 Apr 2016 Post-hoc pooled analysis of FREEDOMS, FREEDOMS II, and LONGTERMS studies assessing the long-term of fingolimod on disability (n=1556) were presented at the 68th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top